A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

DSpace Repositorium (Manakin basiert)

A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Autor(en): Miller, Kurt; Morant, Rudolf; Stenzl, Arnulf; Zuna, Ivan; Wirth, Manfred
Tübinger Autor(en):
Stenzl, Arnulf
Erschienen in: Urologia Internationalis (2016), Bd. 96, H. 1, S. 5-13
Verlagsangabe: Karger
Sprache: Englisch
Referenz zum Volltext: http://dx.doi.org/10.1159/000381589
ISSN: 1423-0399
DDC-Klassifikation: 610 - Medizin, Gesundheit
Dokumentart: Wissenschaftlicher Artikel
Zur Langanzeige

Das Dokument erscheint in: